Idera Pharmaceuticals, Inc. (IDRA) News
Filter IDRA News Items
IDRA News Results
|Loading, please wait...|
Latest IDRA News From Around the Web
Below are the latest news stories about IDERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IDRA as an investment opportunity.
Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better
Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024
Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.
Idera Pharmaceuticals press release (IDRA): Q2 GAAP EPS of -$0.10.Shares +4%.Cash position as of June 30, 2022 was $24.5 million
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. The trial included patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis. Noting that there were more patients with ulcerated lesions in the place
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals (NASDAQ: IDRA) and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new expon